Funder: National Institutes of Health
Due Dates: April 10, 2026 (Forecasted)
Funding Amounts: $50,000–$150,000 per award; up to $4.7M total program funding; approx. 17 awards expected
Summary: Supports early-stage, proof-of-concept technology development for biospecimen analysis, targeting, or quality control in cancer research and clinical care.
Key Information: This is a forecasted opportunity; dates and details may change.